Ideas For Now-

vanzandt said:
Well before we break out the band Stoney, just remember "everyone's a genius in a bull market".
That said, there is no no denying talent obviously. I always say that regardng other areas, but it applies here as well. And these were off the radar picks for the most part.
Don't ever change Stoney.
ET's lucky, Covid has graced us with your diatribe much longer than in years gone by. You are usually long gone by now. Only to return in the Spring.
Now.... have you noticed how the entire world is jumping on our sports betting bandwagon?
It all started with my SBGI dd. ;)
More...

Stoned pencils. I can dig it.
 
The Idea For Today is from Israel. Up 12% yesterday. - Kamada.

To make a long story short. I went through the Post earnings CC Q&A and I remember thinking Ok this is a decent story-- plasma therapy-- but there was no control group and the survival numbers were not jumping off the page. I'll get you these fact... It was something like 7 recoveries without the drug and ten with... Mortality rate was down.- By three!

Yesterday whispers from israel :
Three patients given Kamada 'passive vaccine' recover from COVID, J Post says 16:22
KMDA
The first three patients treated with a new COVID-19 "passive vaccine" developed by Kamada, have recovered from COVID-19 symptoms and been released from the hospital, according to co-developer Hadassah Medical Center, reported The Jerusalem Post

So The Question is did they get lucky and have their " 3 " recoveries all at once sequentially... or is there something else going on here-- and the key difference may be that these patients are receiving a mixed plasma with other people's not just their own...

One of the Analysts who I read his questions in the Q&A came back today with this--

Kamada price target raised to $11 from $7 at Chardan 06:52 KMDA Chardan analyst Keay Nakae raised the firm's price target on Kamada to $11 from $7 and keeps a Buy rating on the shares after the company reported Q2 results and "multiple" stories were published in the Israeli press highlighting the initial positive response observed in the first three patients who were given the company's convalescent plasma-derived hyperimmune globulin product as a potential treatment for SARS-CoV-2 disease. The potential of this product, which takes the concept of convalescent plasma therapy "a step further" by pooling plasma from several donors, drives the price target increase, Nakae tells investors.<-----

---> It has been quite some time since I had the #1 Top Gainer on the Nasdaq---
Several of my clients are very very happy and keep sending me emails-- the trouble is With My Money I SOLD IT! I TOOK a Gain and now I have pain. I Don't have enough money to buy and hold everything! And I shuffle stuff to my great regret.... PLEASE STOP SENDING ME EMAILS THANKING me because I personally want to jump out the window.

Now I take it as a challenge: Can I have the TOP GAIner Again?

A) KMDA.



Top Gainers (NYSE, NASDAQ)

  • GrowGeneration Corp.
    GRWG
 
KMDA 1 year = +63% Gain/6 months = 37% 1 Month = 5%<---

That is like compacting a slinky.... Now it will uncoil.-> NASDAQ |Pre-Market:$10.65+1.65(+18.33%)7:37 AM

CORRECTION) Up 22%
9.00+0.95 (+11.80%)
At close: August 13 4:00PM EDT
11.05+2.05 (22.78%)<----------
Before hours:7:57AM EDT
 
Today is Aug 14.

Aug 21 is about 1 week away.

FLDM Trades for approx $8.00

Investors inFluidigm CorporationFLDM need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 21, 2020 $10.00 Call had some of the highest implied volatility of all equity options today.

Prediction: I hope and Pray $8 becomes $16 in 2 weeks time<----100% in 2 weeks.

Candidate #2) FLDM.
 
QDEL)--$ 250. Expensive for a reason.

Thermo Fisher tried to buy (as they always do) but the shareholders said No!

Quidel price target raised to $363 from $306 at Craig-Hallum 07/31 QDEL Craig-Hallum analyst Alexander Nowak raised the firm's price target on Quidel to $363 from $306 and keeps a Buy rating on the shares following the company's quarterly results. The analyst notes that the Q2 call demonstrated the massive demand for Quidel's COVID tests and the positive effect it is having on margins and profitability.

I like QDEL. Going to have to sell something to get it! And the vicious cycle continues...
 
Anybody heard of BoxLight?

Check this out-- This is from 2 days ago)
Boxlight, Samsung enter strategic partnership for U.S. education market 08:36 BOXL, SSNLF Boxlight (BOXL) and Samsung Electronics America (SSNLF) announced a strategic partnership to bundle classroom displays, classroom software and professional development for the education market. The companies said in a release, "The education bundles combine Samsung display innovations with Boxlight's OKTOPUS education software and online professional development courses. The bundles provide teachers a complete solution that can be easily adopted to create an engaging learning environment for students. Samsung display solutions for education include digital signage, interactive Flip 2 and QBH-TR displays. Boxlight's OKTOPUS software provides a presentation solution that offers subject specific tools for teaching, assessment and polling functions, grading and reporting features, and personal device collaboration. OKTOPUS also allows existing third-party lessons to be uploaded and used in the teaching software. In addition to OKTOPUS, the education bundles include OKTOPUS Blend, a library of over 10,000 master-teacher created lessons, and GameZones, a gaming component that features over 90 games that focus on concepts and skills appropriate for K-8 students.

BOXL- $2.17

Boxlight had a 15M share Spot Secondary priced at $2.00 on 07/28 BOXL The deal priced below the last closing price of $2.85. Maxim acted as sole book running manager for the offering.

Owch! Ok so stk was dead at $2 after the secondary at the end of last month then....$1.90--> to $2.50 on this news of the Samsung partnership.... Then -12% retrace.... to $2.17.... Today looking Up @ $2.30.
 
Hubspot works out of Cambridge USA... is that Boston? I think that's the smart part of Boston... I went to BU on the other side of the Charles River.

Hubspot does some kind of software that helps small businesses. (don't they all).

Usual volume 580K yesterday traded over 1 mil....

Lousy Earnings- HubSpot(NYSE:HUBS) reported Q2 sales of $203.61 million. Earnings fell to a loss of $13.62 million, resulting in a 3.38% decrease from last quarter. HubSpot collected $198.97 million in revenue during Q1, but reported earnings showed a $14.10 million loss.


HubSpot
Tools for customer relationship management (or CRM) are extremely valuable for any size business, but they can be crucial for small businesses. It's hard to keep track of inbound contacts and orders with tools built for large companies, as with salesforce.com, so HubSpot has become a go-to option for smaller companies.

The ability to scale up the offerings as a company grows and to add services like email marketing and customer service for existing customers also keeps growing a business owner's reliance on the HubSpot platform. You can see below that it's driven tremendous growth and high profit margins as well.




The next step for HubSpot is translating growth into earnings, which software companies like this do as they reach scale and their customer base matures. And when earnings begin to improve, this could be a stock that is a great value because of the long-term relationship it has with small-business customers.


HubSpot-$$275
NYSE:HUBS
 
You must log in or register to reply here.
Back
Top